Gilead patents on costly hepatitis C drug challenged in 5 countries
May 20, 2015 at 12:17 PM EDT
NEW YORK, May 20 (Reuters) - A U.S. group is trying to block patents in five countries for Gilead Sciences Inc's costly hepatitis C drug Sovaldi, in a bid to give almost 60 million afflicted people access to cheaper generic versions.
